(Q36909501)

17 August 2017

1 reference

title

Anti-emetic therapy in cancer chemotherapy: current status (English)

1 reference

17 August 2017

1 reference

Jørn Herrstedt

1

1 reference

17 August 2017

Per Dombernowsky

series ordinal

2

1 reference

17 August 2017

publication date

1 September 2007

1 reference

Basic and Clinical Pharmacology and Toxicology

17 August 2017

published in

1 reference

17 August 2017

volume

101

1 reference

17 August 2017

issue

3

1 reference

17 August 2017

page(s)

143-150

1 reference

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2007.00122.X

Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2007.00122.X

Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2007.00122.X

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2007.00122.X

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2007.00122.X

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2007.00122.X

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2007.00122.X

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2007.00122.X

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2007.00122.X

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2007.00122.X

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2007.00122.X

Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2007.00122.X

Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2007.00122.X

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2007.00122.X

Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2007.00122.X

10.1111/J.1742-7843.2007.00122.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference